HighTide Therapeutics Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting
Reuters
Nov 07
HighTide <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting
HighTide Therapeutics Inc. has announced the presentation of new clinical evidence demonstrating the potential renal benefits of its lead asset, HTD1801, in patients with mild renal impairment. The results were presented at the 58th Annual Meeting of the American Society of Nephrology (ASN) in Houston, US. HTD1801 is described as a first-in-class anti-inflammatory metabolic modulator with dual mechanisms of AMPK activation and NLRP3 inhibition, aimed at addressing residual risks associated with cardiovascular-kidney-metabolic diseases. Data supporting these findings were derived from two randomized, double-blind, placebo-controlled Phase III studies. The company notes that HTD1801 has received two Fast Track designations and one Orphan Drug designation from the US FDA. HighTide Therapeutics cautions that there is no guarantee HTD1801 will ultimately be successfully marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.